Eli Lilly and Novo Nordisk can’t keep up with demand for their weight loss medications. In this Viewsroom podcast, Breakingviews columnists discuss the hype among celebrities, the different approaches to prescribing them in the US and Europe, and how they can reshape the world. Visit the Thomson Reuters Privacy Statement for information on our privacy and data protection practices. You may also visit megaphone.fm/adchoices to opt-out of targeted advertising.
Next UK leader will bang head against fiscal roof
Big Macs are pricing out American shoppers
The dollar and the yuan are polar opposites
HSBC’s big pair of shoes will be hard to fill
Clash of the mining titans will get more bruising
US economy is a victim of its own success
Telecom tycoon ensnared by his hefty debt machine
How Boeing’s woes change everything but planes
US antitrust push invites creative dealmaking
Europe’s IPO window opens slowly for buyout barons
Bank crises proved a mixed blessing for rivals
Japan’s rate shift will hit zombie firms hardest
Lower rates, office return will ease property pain
Post-crisis Adani is cranking up his IPO factory
Mining pain may be just getting started
Deal famine is driving private equity evolution
JPMorgan succession is a high-stakes soap opera
Shein’s China and ESG risk puts IPO on iffy ground
Global risk pile-up penetrates Davos bubble
Create your
podcast in
minutes
It is Free